Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | PARP1 | P09874 | 2/20 | 0.58 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30179617 | 1.00 | KDM4E (0.64) | KDM4EHTTPOLBSMN1; SMN2MAPT | |
| Salicylamide SCHEMBL440410 | 0.92 | KDM4E (0.59) | KDM4EHTTPOLBSMN1; SMN2MAPT | |
| SCHEMBL3455066 | 0.87 | HTT (0.77) | KDM4EHTTPOLBSMN1; SMN2MAPT | |
| SCHEMBL14273086 | 0.86 | KDM4E (0.60) | KDM4EHTTPOLBSMN1; SMN2MAPT | |
| SCHEMBL8414408 | 0.85 | L3MBTL1 (0.61) | KDM4EHTTPOLBSMN1; SMN2GLA | |
| SCHEMBL29502958 | 0.85 | KDM4E (0.73) | KDM4EHTTPOLBSMN1; SMN2MAPT | |
| SCHEMBL341639 | 0.85 | KDM4E (0.73) | KDM4EHTTPOLBSMN1; SMN2MAPT | |
| SCHEMBL855090 | 0.84 | MAPT (0.78) | KDM4EHTTSMN1; SMN2MAPTPARP1 | |
| SCHEMBL7718767 | 0.84 | MAPT (0.59) | KDM4EHTTSMN1; SMN2MAPTPARP1 | |
| SCHEMBL27537822 | 0.82 | MAPT (0.62) | KDM4EHTTMAPTPARP1CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1972 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| CN-118340907-A | Polymer conjugates comprising bioactive agents | 波利艾克蒂瓦有限公司 | 2024-07-16 | — | — | CN | claimed |
| US-20240041935-A1 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2024-02-08 | — | — | US | claimed |
| CN-113718256-B | Copper etching liquid and application thereof in wafer level packaging | 浙江奥首材料科技有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-113718256-A | Copper etching liquid and application thereof in wafer level packaging | 浙江奥首材料科技有限公司 | 2021-11-30 | — | — | CN | claimed |
| US-11167065-B2 | Shellac and paclitaxel coated catheter balloons | EUROCOR TECH GMBH (DE) | 2021-11-09 | — | — | US | claimed |
| CN-107823719-B | Balloon surface coating | 德国凯德诺有限责任公司 | 2021-01-29 | — | — | CN | claimed |
| CN-107823721-B | Balloon surface coating | 德国凯德诺有限责任公司 | 2021-01-29 | — | — | CN | claimed |
| CN-107823720-B | Balloon surface coating | 德国凯德诺有限责任公司 | 2021-01-29 | — | — | CN | claimed |
| EP-1178783-B1 | DEVICE AND USE FOR INCREASING THE TRANSDERMAL PERMEATION OF MEDICAMENTS | LOHMANN THERAPIE SYST LTS (DE) | 2004-04-21 | — | — | EP | claimed |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | MCNEIL-PPC, INC | 2003-12-25 | — | — | US | claimed |
| WO-2003094990-A1 | COMPOUNDS AND METHOD FOR COATING SURFACES IN A HAEMOCOMPATIBLE MANNER | HEMOTEQ GMBH (DE) | 2003-11-20 | — | — | WO | claimed |
| US-20030180357-A1 | Pharmaceutical tablet | MCNEIL-PPC, INC | 2003-09-25 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| JP-2003500349-A | — | — | 2003-01-07 | — | — | JP | claimed |
| EP-1212317-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GlaxoSmithKline S.p.A. (IT) | 2002-06-12 | — | — | EP | claimed |
| EP-1178783-A1 | DEVICE AND METHOD FOR INCREASING THE TRANSDERMAL PERMEATION OF MEDICAMENTS | LTS Lohmann Therapie-Systeme AG (DE) | 2002-02-13 | — | — | EP | claimed |
| WO-2001002388-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GLAXOSMITHKLINE S.P.A. (IT) | 2001-01-11 | — | — | WO | claimed |
| WO-2000071100-A1 | DEVICE AND METHOD FOR INCREASING THE TRANSDERMAL PERMEATION OF MEDICAMENTS | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2000-11-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030180357-A1 | Pharmaceutical tablet | GYPA, SORD, SRI | KDM4E 3204/4885HTT 958/4885POLB 4083/4885 |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | SI, UGGT1, GYPA | KDM4E 2862/4885HTT 2028/4885POLB 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.